- Home
- MRM vs LGVN Comparison
MRM vs LGVN Comparison
Compare MRM & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | LGVN |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRM | LGVN |
|---|---|---|
| Price | $1.06 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 170.1K | ★ 8.5M |
| Earning Date | 05-22-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,183.95 |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.48 |
| 52 Week High | $4.45 | $1.83 |
Technical Indicators
Market Signals| Indicator | MRM | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 23.18 | 56.78 |
| Support Level | $1.10 | $0.60 |
| Resistance Level | $1.64 | $0.99 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 22.00 | 39.11 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.